Phase 1

Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults

March 15, 2019

https://clinicaltrials.gov/ct2/show/NCT03401346?type=Intr&cond=Migraine&lupd_s=03%2F01%2F2019&lupd_d=14

Condition : Migraine Headache

Interventions : Combination Product: INP104; Drug: Dihydroergotamine Mesylate (DHE); Combination Product: Migranal Nasal Spray

Sponsor : Impel NeuroPharma Inc.

Completed

Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults

NCT03401346

Wed, 17 Jan 2018 12:00:00 EST

Last Update Posted: 03/15/19 11:30AM

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

March 14, 2019

https://clinicaltrials.gov/ct2/show/NCT03874832?type=Intr&cond=Migraine&lupd_s=02%2F28%2F2019&lupd_d=14

Conditions : Migraine With Aura; Migraine Without Aura; Migraine

Intervention : Drug: Dihydroergotamine

Sponsor : Satsuma Pharmaceuticals, Inc.

Completed

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

NCT03874832

Thu, 14 Mar 2019 12:00:00 EDT

Last Update Posted: 03/14/19 09:43AM

Back to top